Cardiome Announces Shareholder Meeting Voting Results

Cardiome Pharma (NASDAQ:CRME; TSX:COM) shared the voting results from the company’s 2017 annual general and special meeting of shareholders.
As quoted in the press release:

A total of 24,583,372 common shares were voted in connection with the meeting, representing approximately 77.00% of the issued and outstanding common shares of the company. Shareholders voted as follows:
Election of Directors
By resolution passed by ballot vote, the following six nominees proposed by management were elected as directors of Cardiome to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Richard M. Glickman	14,080,137	87.60%	1,992,340	12.40%
W. James O’Shea	15,466,194	96.23%	606,283	3.77%
William L. Hunter	15,543,529	96.71%	528,948	3.29%
Mark H. Corrigan	15,465,791	96.23%	606,686	3.77%
Arthur H. Willms	15,543,282	96.71%	529,195	3.29%
Robert J. Meyer	15,544,284	96.71%	528,193	3.29%

Appointment of Auditor
By resolution passed by show of hands, KMPG LLP, Chartered Accountants, was appointed auditor of the company for the ensuing year.
Approval of Amendments to and Unallocated Entitlements under the Restricted Share Unit Plan
By resolution passed by ballot vote, amendments to the Company’s Restricted Share Unit Plan were ratified, confirmed and approved, and the Restricted Share Unit Plan was re-approved and all unallocated entitlements under the Restricted Share Unit Plan were approved, and the Company was granted the ability to continue granting restricted share units under the Restricted Share Unit Plan until June 20, 2020.

Click here to read the full press release.